Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01677390 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
A Phase 1 study, sponsored by Seagen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT01677390 is a Phase 1 study that was terminated before completion, run by Seagen. The registered enrollment target is 4 participants.
The verdict
NCT01677390, a Phase 1 study, was terminated before completion, sponsored by Seagen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in combination with everolimus in patients with CD70-positive metastatic renal cell carcinoma.
Interventions
- DRUG everolimus
- DRUG SGN-75
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2012-08 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01677390
The ClinicalTrials.gov registry entry for NCT01677390 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which everolimus is the first listed.
NCT01677390 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01677390 about?
NCT01677390 is a clinical study titled "A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma". This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in combination with everolimus in patients with CD70-positive metastatic renal cell carcinoma.
What is the current status of trial NCT01677390?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2012-08. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01677390?
The interventions under investigation include: everolimus (DRUG), SGN-75 (DRUG).
Who is sponsoring clinical trial NCT01677390?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.